Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 7/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.32 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.32 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.32 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.32 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.32 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.32 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | CTSA | P10619 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17752357 | 0.86 | PDGFRB (0.44) | SCN9AKIT | |
| SCHEMBL15031948 | 0.86 | PDGFRB (0.44) | SCN9AKIT | |
| SCHEMBL16303551 | 0.85 | FPR2 (0.36) | SCN9AKITABCB1FPR2 | |
| SCHEMBL17752330 | 0.78 | HTR2A (0.40) | SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL15031956 | 0.78 | HTR2A (0.40) | SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL16294426 | 0.76 | EGFR (0.37) | SCN9ASMN1; SMN2NPC1RAB9ACYP2C9 | |
| SCHEMBL16296854 | 0.75 | SCN9A (0.37) | SCN9ASMN1; SMN2NPC1RAB9AKIT | |
| SCHEMBL15031958 | 0.74 | KIT (0.46) | KITABCB1ALDH1A1 | |
| SCHEMBL17752371 | 0.71 | PDGFRB (0.46) | KITALDH1A1FPR2CTSA | |
| SCHEMBL17752376 | 0.70 | FPR2 (0.44) | SCN9ASMN1; SMN2NPC1FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776995-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160137636-A1 | Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors | AMGEN INC. | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137636-A1 | Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors | SCN7A, SCN1A, SCN5A | SCN9A 11/4885SMN1; SMN2 386/4885NPC1 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.